|Titre :||Coordination of drug policy in the European Union 2000-2004. Contribution to the evaluation of the EU action plan on drugs (2000-2004)|
|Auteurs :||OEDT = EMCDDA|
|Type de document :||Rapport|
|Editeur :||Lisbon : OEDT / EMCDDA, 2004|
|Format :||13 p.|
|Discipline :||PRE (Prévention / Prevention)|
Thésaurus TOXIBASEEVALUATION ; PLANIFICATION SANITAIRE ; POLITIQUE ; EFFICACITE ; PARTENARIAT
Thésaurus GéographiqueEUROPE ; UNION EUROPEENNE
For the last 20 years, coordination in the field of drugs has been seen as an integral part of drug policy and an indispensable tool for ensuring its effectiveness. This thematic paper looks at the formal characteristics of drug coordination systems in EU countries and at the extent to which the EU strategy and action plan may have influenced their development.
The principle of coordination was first identified in the EU in the mid-1980s and has been underlined in all EU drug plans since the first in 1990. The current action plan calls on countries to set up a coordination system and appoint a national drug coordinator. It also requests the European Commission, with assistance from the EMCDDA, to look into how coordination arrangements could be improved - this resulted in the European Commission 'Communication on coordination on drugs in the European Union' in 2003.
Coordination is often seen as a 'positive aspect of performance' and is viewed as a necessary element to increase productivity or global efficiency of a service. But the paper says that there is no uniform definition of the term: 'although there is a consensus on the need for coordination, there is still the question of what it should consist of'.
The EMCDDA reports increased levels of activity in coordination over the last four years and states that the EU strategy and action plan have been an incentive. However, the mere presence of a coordinating structure is insufficient proof of an efficient mechanism, it says. Scientific research is needed into whether coordination renders the response to the drug problem more efficient. In this light, the new EU strategy could look at how to promote research into best practice among drug coordination mechanisms in Europe.
|Domaine :||Drogues illicites / Illicit drugs|
|Affiliation :||EMCDDA 'Strategies and Impact' Programme, Lisbon, Portugal|
|Titre précédent :|
|Titre suivant :|
Documents numériques (1)
Adobe Acrobat PDF